Industry

Janssen Receives Positive CHMP Opinion for IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

The positive opinion is based on Phase 3 GLOW and Phase 2 CAPTIVATE study results, which investigated the efficacy and safety of ibrutinib plus venetoclax in patients with previously untreated CLL1,2 If approved, this will be the first all-oral, once daily, fixed-duration, combination regimen for first-line treatment of CLL BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies … [Read more…]

Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia

CF602’s unique mechanism of action enables potential treatment of diabetic patients and may offer an alternative to PDE5 (Viagra, Cialis, Levitra, and Stendra) non-responders accounting for 30-35% of the $3.6 billion ED market Patents granted in numerous healthcare markets including the U.S., Australia, and Japan PETACH TIKVA, Israel–(BUSINESS WIRE)–$CANF—Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: … [Read more…]

Flow Beverage Corp. Announces Official Sponsorship with Pride Toronto

Flow sponsorship with Pride Toronto promotes both sustainable and healthy choices for consumers TORONTO–(BUSINESS WIRE)–Flow Beverage Corp. (TSX:FLOW; OTCQX:FLWBF) (“Flow” or the “Company”) today announced its official sponsorship of Pride Toronto, participating in various events throughout June to help inspire people to make more sustainable and healthy choices for themselves and the planet. Flow will … [Read more…]

 Tigerlily Foundation and Labcorp Collaborate to Increase Clinical Trial Diversity for Women of Color

BURLINGTON, N.C. & ALDIE, Va.–(BUSINESS WIRE)–Labcorp, a leading global life sciences company, and Tigerlily Foundation (Tigerlily), a leading breast cancer patient advocacy organization, today announced a new collaboration to increase clinical trial diversity for women of color and co-create health equity solutions. Labcorp has signed Tigerlily’s #InclusionPledge for Black Women, joining other healthcare and life … [Read more…]

European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection

Approval based on recurrence-free survival and distant metastasis-free survival benefit demonstrated by KEYTRUDA in the Phase 3 KEYNOTE-716 trial KEYTRUDA is the first anti-PD-1 immunotherapy approved in the EU for patients 12 years and older as adjuvant treatment across stage IIB, IIC and III melanoma following complete resection and for the treatment of advanced (unresectable … [Read more…]

Magellan Healthcare Provides Resources in Support of BIPOC Mental Health Awareness Month in July

FRISCO, Texas–(BUSINESS WIRE)–Magellan Healthcare, the behavioral and specialty healthcare segment of Magellan Health, Inc., today announced resources and programs in support of Black, Indigenous and People of Color (BIPOC) Mental Health Awareness Month in July. One in five Americans has been diagnosed with a mental health or substance use condition.1 While BIPOC experience relatively similar … [Read more…]

Global Oscillating Positive Expiratory Pressure (OPEP) Devices Market Report: Estimated Growth of 5.2% to $179.3 Million by 2028 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Oscillating Positive Expiratory Pressure Devices Market Forecast to 2028 – COVID-19 Impact and Global Analysis by Product, Indication, and Distribution Channel” report has been added to ResearchAndMarkets.com’s offering. The oscillating positive expiratory pressure (OPEP) devices market is expected to grow from US$ 125.66 million in 2021 to US$ 179.34 million by 2028; … [Read more…]

Peripheral T-Cell Lymphomas Drugs Market Pipeline Report 2022: Development by Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Peripheral T-Cell Lymphomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of … [Read more…]

Vulvar Cancer Drugs Market Pipeline Report 2022: Development by Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Vulvar Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive information on the therapeutics under development for Vulvar Cancer, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and … [Read more…]

Global Spinal Fusion Devices Market Report 2022-2027: Growth of 4.6% Fueled by Rising Number of Novel Innovations Across the Spinal Fusion Market – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Spinal Fusion Devices Market Size, Share & Industry Trends Analysis Report By Surgery, By Type, By End User (Hospitals, Specialty Clinics, and Others), By Regional Outlook and Forecast, 2022 – 2028” report has been added to ResearchAndMarkets.com’s offering. The Global Spinal Fusion Devices Market size is expected to reach $9.7 billion by … [Read more…]